ArticleNature cell biology2026
Gain-of-function suppressors restore microtubule dynamics and rescue dominant-negative tubulinopathies.
Article in Nature cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Missense mutations in tubulin-coding genes often exert dominant-negative effects on microtubule (MT) assembly, leading to developmental disorders collectively known as tubulinopathies. Here we performed suppressor screens in Caenorhabditis elegans and identified three functionally distinct classes of missense suppressors that counteract toxic α- and β-tubulin mutants. Intergenic suppressors-missense variants in the reciprocal tubulin gene-restore MT architecture via two distinct mechanisms: assembly-defective variants competitively exclude mutant tubulins, whereas assembly-competent variants modulate MT dynamics. These mechanisms are conserved and recapitulated in human cells and murine oocytes, where selected intergenic suppressors rescue pathogenic tubulin-induced MT defects and outperform wild-type tubulin supplementation. A systematic mutational analysis of TUBA1A further defines a landscape of gain-of-function assembly-competent suppressors, supported by molecular simulations showing restoration of protofilament geometry. Together, our results provide a structural and functional framework for tubulin suppression and highlight intergenic suppressors as potential candidates for precision therapeutics targeting dominant tubulinopathies.
Identifiers
42728306What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.